Yimingangke-B (01541): IMC-003/IMM72 has been approved by the National Medical Products Administration for clinical trials.

Smart Finance APP News, Yimingon Technology-B (01541) announced that the group has obtained approval for a new drug clinical trial (IND) from the China National Medical Products Administration ("National Medical Products Administration") to start IMC-003/IMM72 clinical trial for the treatment of pulmonary arterial hypertension (PAH).